This is a parallel group, Phase 2, 2-arm study to measure the treatment effect and safety of rilzabrutinib dose 1 or rilzabrutinib dose 2 in participants with Graves' disease, with and without Graves' orbitopathy, aged 18 years or older.
Study details include:
* Screening period (up to 4 weeks).
* Treatment period (up to 16 weeks).
* Follow-up period (4 weeks). The number of visits will be up to 13.
Protocol Amendment History
7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2025-05-14; most recent amendment 2026-07-06.
Status change: Not Yet Recruiting → Recruiting2025-09-04